Cardiovascular Innovations and Applications

Call Directions Website Contact the practice

Cardiovascular Innovations and Applications A platinum open access & the official journal of the Great Wall International Congress of Cardiology

Cardiovascular Innovations and Applications (CVIA) publishes focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability in order to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification. CVIA also welcomes commentaries, case studies and reports, letters to the editor, methodology papers related to clinical trials, education and training articles, techniques and videos. CVIA was founded on the occasion of the 25th anniversary of the GW-ICC in 2014 by Professor Dayi Hu, president of the GW-ICC and past president of the Chinese Society of Cardiology, and C. Richard Conti, MD, a past president of the American College of Cardiology and former Editor of Clinical Cardiology. The GW-ICC is one of the largest congresses in the Asian-Pacific region and is the most comprehensive and influential academic conference on cardiology. Held as a regular annual conference since 1990, GW-ICC has provided a platform for continuing education in cardiovascular disease diagnosis, treatment, and technology training, through events that leverage the expertise of internationally renowned cardiologists and scholars from the United States, Europe and Asia. The journal is published by Compuscript on behalf of the World Journals (Beijing) Medical Technology Co., Ltd. Compuscript is an international company based in Shannon, Ireland.

Reviewing inflammatory mechanisms across heart failure types and evidence from clinical trials, this study shows that al...
29/10/2026

Reviewing inflammatory mechanisms across heart failure types and evidence from clinical trials, this study shows that although is closely linked to pathogenesis and prognosis, current anti-inflammatory approaches have generally not improved clinical outcomes.
: https://doi.org/10.15212/CVIA.2024.0050

A review of contemporary evidence and updated international guidelines highlights   as a first-line therapy for selected...
27/10/2026

A review of contemporary evidence and updated international guidelines highlights as a first-line therapy for selected patients while examining its role within broader treatment strategies, including management of heart failure. Mayo Clinic

: https://doi.org/10.15212/CVIA.2025.0001

A clinically applicable nomogram for post-CRT mortality prediction demonstrated outstanding discrimination (AUC >0.90), ...
23/10/2026

A clinically applicable nomogram for post-CRT mortality prediction demonstrated outstanding discrimination (AUC >0.90), with NOAF emerging as a key predictor that reflects impaired atrioventricular synchrony and is independently associated with adverse outcomes in patients receiving CRT.
: https://doi.org/10.15212/CVIA.2025.0016

When antihypertensive medication is taken may affect blood pressure control, but timing alone may not determine   risk.B...
22/10/2026

When antihypertensive medication is taken may affect blood pressure control, but timing alone may not determine risk.

By examining circadian variation in BP regulation, vascular function, autonomic activity, renal sodium handling, and RAAS signaling, this commentary highlights why personalized dosing strategies may be more clinically relevant than routine bedtime administration for all patients.

: https://cvia-journal.org/antihypertensive-dosing-time-cardiovascular-outcomes/

Could targeting mitochondrial quality control (MQC) pathways interrupt the cycle of  , chronic inflammation, and lipid a...
22/10/2026

Could targeting mitochondrial quality control (MQC) pathways interrupt the cycle of , chronic inflammation, and lipid accumulation that drives ?

This review suggests that interventions aimed at MQC regulators may offer new therapeutic opportunities. Zhejiang University

: https://doi.org/10.15212/CVIA.2025.0013

In patients with intermediate-risk pulmonary embolism, percutaneous mechanical   using the Tendvia system was associated...
20/10/2026

In patients with intermediate-risk pulmonary embolism, percutaneous mechanical using the Tendvia system was associated with a significant reduction in the RV/LV diameter ratio while demonstrating minimal bleeding risk, highlighting the need for future investigations in high-risk acute . Shanghai Jiao Tong University Peking University
: https://doi.org/10.15212/CVIA.2024.0066

In a prospective trial of intermediate-risk  , a large-diameter thrombus aspiration and mechanical   device was associat...
16/10/2026

In a prospective trial of intermediate-risk , a large-diameter thrombus aspiration and mechanical device was associated with improved right ventricular function and reduced thrombus burden, highlighting the potential of catheter-based as a minimally invasive treatment approach. Xiamen University

: https://doi.org/10.15212/CVIA.2024.0055

The CLEAR study demonstrated that mechanical   achieved significant reductions in RV/LV ratio while maintaining a low in...
15/10/2026

The CLEAR study demonstrated that mechanical achieved significant reductions in RV/LV ratio while maintaining a low incidence of major bleeding and procedural complications, supporting broader consideration of catheter-directed approaches in . Peking Union Medical College / Chinese Academy of Medical Sciences
: https://doi.org/10.15212/CVIA.2024.0073

Address

Bay K, Shannon Industrial Estate
Shannon
V14WK53

Alerts

Be the first to know and let us send you an email when Cardiovascular Innovations and Applications posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Cardiovascular Innovations and Applications:

Share

Nearby clinics